Clinical Trial Update: A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy. [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the hematologic response (hemoglobin increase) to PROCRIT (epoetin alfa) given at 80,000 units weekly in cancer patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Cancer

Drugs mentioned

• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Anemia, Cancer | Phase 3 | Status: COMPLETED